We are live on ! Find out more
GNMX

Aevi Genomic Medicine Inc
GNMX

Delisted

GNMX was delisted on the 3rd of February, 2020.

Back to rankings

63 hedge funds and large institutions have $81.6M invested in Aevi Genomic Medicine Inc in 2015 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 28 increasing their positions, 9 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

600% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 2

211% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 9

49% more capital invested

Capital invested by funds: $54.9M → $81.6M (+$26.7M)

24% more funds holding

Funds holding: 51 → 63 (+12)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
63
Holders Change
+12
Holders Change %
+23.53%
% of All Funds
1.65%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
14
Increased
28
Reduced
9
Closed
2
Calls
$284K
Puts
–
Net Calls
+$284K
Net Calls Change
-$29K

Top Buyers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
+$10.2M
2
Jennison Associates
Jennison Associates
New York
+$6.15M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$6.11M
4
BBA
Baker Bros. Advisors
New York
+$5.19M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$5.19M

Top Sellers

Rank Fund Capital Flow
1
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$614K
2
BGA
Belmont Global Advisors
Texas
-$611K
3
Morgan Stanley
Morgan Stanley
New York
-$43K
4
PVH
Psagot Value Holdings
Israel
-$14.9K
5
BA
BlackRock Advisors
Delaware
-$11.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
CD
26
Carl Domino
Florida
$205K – – –
Millennium Management
27
Millennium Management
New York
$196K +$51.5K +7,581 +30%
TA
28
Teachers Advisors
New York
$184K +$37.8K +5,574 +22%
Charles Schwab
29
Charles Schwab
California
$143K – – –
WPC
30
White Pine Capital
Minnesota
$120K – – –
VanEck Associates
31
VanEck Associates
New York
$120K +$15.5K +2,279 +13%
AQR Capital Management
32
AQR Capital Management
Connecticut
$114K +$129K +18,927 New
RhumbLine Advisers
33
RhumbLine Advisers
Massachusetts
$109K +$28K +4,130 +29%
New York State Common Retirement Fund
34
New York State Common Retirement Fund
New York
$93K – – –
CDH
35
Charles D. Hyman
$91K +$14.6K +2,143 +16%
PVH
36
Psagot Value Holdings
Israel
$90K -$14.9K -2,197 -13%
Wells Fargo
37
Wells Fargo
California
$85K +$83.2K +12,255 +631%
NFA
38
Nationwide Fund Advisors
Ohio
$82K +$21.6K +3,177 +30%
Goldman Sachs
39
Goldman Sachs
New York
$80K -$4.81K -709 -5%
CG
40
Cutler Group
California
$73K +$82.8K +12,197 New
AIM
41
Alambic Investment Management
California
$68K +$76.2K +11,220 New
BA
42
BlackRock Advisors
Delaware
$66K -$11.9K -1,752 -14%
AIG
43
American International Group
New York
$59K -$115 -17 -0.2%
Morgan Stanley
44
Morgan Stanley
New York
$43K -$43K -6,335 -47%
SO
45
STRS Ohio
Ohio
$32K – – –
Deutsche Bank
46
Deutsche Bank
Germany
$32K +$6.37K +938 +20%
BNP Paribas Financial Markets
47
BNP Paribas Financial Markets
France
$24.6K +$5.14K +757 +23%
UBS Group
48
UBS Group
Switzerland
$23K +$5.18K +763 +26%
Bank of America
49
Bank of America
North Carolina
$21K +$22.6K +3,324 +1,561%
Victory Capital Management
50
Victory Capital Management
Texas
$18K +$1.1K +162 +6%
1
2
3

GNMX Hedge Fund Activity: Q4 2015 in Review

63 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Aevi Genomic Medicine Inc (GNMX) for Q4 2015, worth a combined $81.6M — up 49% from $54.9M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new GNMX positions and 2 closed out — a net gain of 12 holders — while 28 added to existing stakes and 9 trimmed.

The largest buyer was Broadfin Capital, adding an estimated $10.2M. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $614K sold.

  • 63 institutional investors held Aevi Genomic Medicine Inc (GNMX) as of Q4 2015, up from 51 in Q3 2015.
  • Funds reported $81.6M of Aevi Genomic Medicine Inc stock for Q4 2015, up 49% quarter-over-quarter.
  • 14 funds opened new Aevi Genomic Medicine Inc positions in Q4 2015 and 2 closed out, a net change of +12 holders.
  • The largest Aevi Genomic Medicine Inc buyer in Q4 2015 was Broadfin Capital, an estimated $10.2M added.
  • The largest Aevi Genomic Medicine Inc seller in Q4 2015 was Alyeska Investment Group, an estimated $614K sold.

Based on aggregated 13F filings for Q4 2015.